Aktiengesellschaft Bayer serves as Executive at CRISPR Therapeutics AG, where they oversee executive responsibilities. Since joining the company, Aktiengesellschaft Bayer has executed 4 insider transactions totaling $27.0M, demonstrating a bullish approach to their equity position. Their most recent transaction on Jun 22, 2021 involved purchasing 750,000 shares valued at $15.0M.
Aktiengesellschaft Bayer currently holds 12,675,838 shares of CRISPR Therapeutics AG (CRSP), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Aktiengesellschaft Bayer has been a net buyer of CRSP stock. They have purchased $27.0M and sold $0 worth of shares.
Aktiengesellschaft Bayer's most recent insider trade was on Jun 22, 2021, when they purchased 750,000 shares at $20.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Jun 22, 2021 | IPSC | $0 | Conversion | 10,390,600 | $N/A | Discretionary |
| Jan 5, 2018 | CRSP | $12.0M | Purchase | 527,472 | $22.75 | Discretionary |